H & J CRO International, Inc.   Report issue

For profit Phase 1 Phase 4
Founded: Beijing China (2003)

Organization Overview

First Clinical Trial
2015
NCT02553187
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

H & J CRO International, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

kanglaite (1 trial)

Drugs in Phase 1 Trials (1)

Chiauranib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cachexia (Phase 4)

Wasting Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2